Frédéric Féru

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular BiologyNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC”.

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC

Bioorganic & Medicinal Chemistry Letters(2022)10.1016/j.bmcl.2022.128718

N/A

0DataRank · unranked

23 citations

David E. Heppner, Tyler S. Beyett, Ciric To, Seth C. Azevedo, Jaebong Jang +11 more

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-zzfc3

N/A

0DataRank · unranked

2 citations

Surbhi P. Chitnis, Calvin D Pham, Tahereh Damghani, Ilse K. Schaeffner, Matthew Q. Deng +13 more

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c02311

N/A

0DataRank · unranked

8 citations

Surbhi P. Chitnis, Calvin D. Pham, Tahereh Damghani, Kishan B. Patel, Mareike Möllers +17 more